Panel demonstrates significance of assessing biomarkers that change from response to the presence of cancer cells, making it valuable for studying the biochemical mechanisms and signals of cancer
Millipore has announced the availability of the Beadlyte human cancer biomarker panel.
The panel includes a Five-plex containing the biomarkers: macrophage, migration inhibitory factor (MIF), prolactin, CA-125, leptin and osteopontin (OPN); and a single plex IGF-II assay.
Each of the biomarkers has been identified in various tumour types including lung, breast, prostate and colorectal.
Gil Mor of Yale University used the panel in research to detect all stages of ovarian cancer.
The profile of the six biomarkers isolated from serum was used with a unique algorithm developed by Mor's laboratory to discriminate accurately between ovarian cancer patients and healthy subjects.
The assays can be used to quantify these biomarkers in serum, plasma and cell/tissue culture supernatant samples.
Each panel includes all components to run the assay, standards and quality controls for each plex and can be easily adapted for high throughput automation.
The panel is highly sensitive, offering excellent intra- (<11%) and inter-assay (<10%) precision.